Evidence map›Paper›PMID 41238810›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2026

Effects of sacubitril/valsartan according to daily salt intake and comparison with thiazide add-on treatment in patients with uncontrolled hypertension.

Kyoji Chiba, Mari Sotozawa, Kazuo Kobayashi, Hiromichi Wakui, Keiichi Chin, Hideo Shimura, Shun Ito, Toshinao Tsuge, Hiroyuki Sakai, Takayuki Furuki and 10 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kyoji Chiba *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Mari Sotozawa *Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuo KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. k-taishi@xc4.so-net.ne.jp.
Hiromichi WakuiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Keiichi ChinCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hideo ShimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Shun ItoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Toshinao TsugeCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hiroyuki SakaiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Takayuki FurukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Atsushi MatsuzakiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Shinichi NakajimaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Nobukazu TakadaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hareaki YamamotoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Hiroshi TakedaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Takamasa IwasawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.
Togo AoyamaDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara, Japan.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Akira KanamoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Kanagawa Prefecture, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This post-hoc study had two aims: first, to evaluate the effects of sacubitril/valsartan on salt intake, and second, to compare sacubitril/valsartan with thiazide diuretics in patients with uncontrolled hypertension and high salt intake. Among patients with uncontrolled hypertension despite treatment with a combination of renin-angiotensin system inhibitors and calcium channel blockers, those who were switched to sacubitril/valsartan (sacubitril/valsartan group, n = 351) and those who were prescribed a thiazide add-on (thiazide group, n = 260) were included. The participants were divided into two groups (high and low salt groups) based on their daily salt intake. To adjust confounding factors, A propensity score analysis with inverse probability weighting was performed to compare both groups. A cutoff value of 8.2 g of daily salt intake was calculated using receiver operating characteristic analysis. In the sacubitril/valsartan group, no significant differences in blood pressure were observed between the high and low salt groups. Within the high salt group, the systolic home morning blood pressure was lower in the sacubitril/valsartan group than in the thiazide group by -4.0 mmHg [95% confidence interval: -7.0, 0.9] (p = 0.01). Significantly lower uric acid and glycated hemoglobin A

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsHypertensionSodium Chloride, DietarySodium Chloride Symporter InhibitorsTetrazolesThiazidesValsartanAgedBiphenyl CompoundsBlood PressureDrug CombinationsDrug Therapy, CombinationFemaleHumansAminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationSodium Chloride, DietarySodium Chloride Symporter InhibitorsTetrazolesThiazidesValsartanImplemental hypertensionMorning hypertensionSacubitril/valsartanSalt intakeThiazide diuretics

Identifiers

PMID41238810

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.